THE FANCONI ANEMIA BRCA PATHWAY AS A PREDICTOR OF BENEFIT FROM BEVACIZUMAB IN A LARGE PHASE II CLINICAL TRIAL IN OVARIAN CANCER

University Of Washington, Seattle WA

Investigators